Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Sales Volume, ASP & Number of Procedure Conducted by Product Type, Application & End-User The global congestive heart failure (CHF) treatment devices market will witness a robust CAGR of 8.31%, valued at $17.53 billion in 2021, expected to appreciate and reach $35.96 billion by 2030, confirms Strategic Market Research. North America leads the market share, followed by the European Union. Cardiovascular Diseases are Majorly Classified into Six Types Coronary Artery Disease (Due to Narrowing of Arteries) Heart Valve Disease (Due to Malfunctioning of Valve) Arrhythmia (Due to Abnormal Heart rhythm) Congestive Heart Failure (CHF) or Heart Failure (Due to Loss of Pumping Strength) Heart Muscle Disease (Due to Thickening of Heart Valve) Congenital Heart (Acquired by birth) According to the study published in the European Society of Cardiology journal, the number of people with heart failure has roughly doubled in the previous three decades. The above estimate suggests that 70 million people in 2022 will suffer from heart failure worldwide. Congestive Heart failure is a chronic (long-term) progressive condition when the heart cannot efficiently pump enough oxygen-rich blood to the remaining part of the body. Over time, the heart muscle loses its capacity to contract or has a mechanical defect preventing blood circulation. As a result, it can't cope with the body's demands, and blood is retrieved to the heart faster as compared to its pumping out, causing it to get congested or backed up. The weakening of the heart's pumping ability causes congestion of blood in the lungs, feet, and legs, called edema, leading to tiredness and shortness of breath. The Most Common Reasons of Congestive Heart Failure are Coronary artery disease. Diabetes High blood pressure Previous heart attack Cardiomyopathy Left-sided CHF is the most common kind of CHF. It occurs when the left ventricle doesn't properly pump blood out to the body. There are two kinds of left-sided CHF: Systolic heart failure (Ineffective contraction of the heart) and Diastolic failure (ineffective relaxation of the heart). Systolic dysfunction is treatable with various medications. However, we have yet to establish the benefits of medicines for people with diastolic heart failure. Various tests are used to diagnose heart conditions like Blood-Test ( Lipid Profile), Chest X-Ray, ECG, Echocardiogram, Stress Tests, Cardiac catheterization and MRI. Drivers - Lifestyle changes, High-stress levels, Dietary habits, and Comorbidity Key factors that vitalize the growth of the Congestive Heart Failure (CHF) Treatment Devices Market Trend:- Lifestyle Changes- Poor diet, lack of exercise, unhealthy weight gain, increased smoking, and excessive alcohol intake increase the risk of cardiac Failure. High-Stress levels- Worry, stress, anger, and sadness among employees worldwide have risen over the past decade. According to Gallup Global Emotions Survey 2019, around one-third of people worldwide reported feeling stressed, worried, and angry. Comorbidities- In addition, chronic heart failure is driven by disorders like coronary artery disease, sleep apnea, heart defects, irregular heartbeats, diabetes mellitus, obesity, and kidney difficulties, which synergistically influence the prevalence of chronic heart failure. As per AME Medical Journal, The most frequent causes of HF with known etiology is ischemic heart disease (42.3% of all cases), followed by chronic obstructive pulmonary disease (37.0%), mitral valve disease (4.3%), aortic valve disease (3.4%), rheumatic heart disease (3.0%), myocarditis (2.6%) and endocarditis (1.4%). Rising Old Age Population- Since CHF is more common in the elderly population; they are the major acquirers and users of CHF Treatment devices. According to World Bank data and World Population Prospects, the share of the old age population in CHF Treatment devices (65 years and more) will rise from 9.32% in 2020 to 16% by 2050. Restraints - Cost, Reimbursement Procedures However, stringent regulatory requirements, the high cost of these devices, and unfavorable reimbursement policies will likely hamper the industry's growth. According to cost-of-illness studies on heart failure published in PubMed, The total annual costs per patient ranged from $868 for South Korea to $25,532 for Germany. The global economic burden of CHF is estimated at $108 billion per annum, with $65 billons attributed to direct and $43 billion to indirect costs. Opportunities High Incidence-Increasing demand and decreasing willingness for organ donation, the need for safe and effective therapy, and the increasing prevalence of chronic heart failure is anticipated to drive the worldwide demand for these devices. As per the research published by CDC (Centers for Disease Control and Prevention), more than 6 Mn adults in the USA have heart failure, and over 23 million worldwide. Health expenditure- Supporting government laws and initiatives in emerging economies and improving healthcare infrastructure to raise public knowledge of CVDs are growth boosters for the total industry. According to a Journal published in the National Library of Medicine (NLM), Heart Failure was responsible for an estimated health expenditure of around USD 31 Bn, which is equivalent to more than 10 % of the total health expenditure for cardiovascular diseases in the United States (US). Technological Advancements- With recent dramatic leaps in sensor and soft robotics technology, scientists are turning to innovative medical devices for heart failure to prolong the life of patients. Demographic and Regional Opportunities- Congestive heart failure is a prevalent ailment among the elderly. Congestive heart failure strikes netizens over the age of 75 ten times more frequently than it does to the younger ones. The research of the Department of Economic and Social Affairs estimates around 703 million people aged 65 or over in 2019 worldwide. Eastern and South-Eastern Asia region was home to the largest number of the older population (261 million), followed by Europe and Northern America (over 200 million). Market Analysis Of Different Segments Covered in the Report Based on Product Cardiac Pacemaker Implantable Cardioverter Defibrillators (ICDs) Cardiac Resynchronization therapy devices (CRT) Counter Pulsation Devices Ventricular Assist Devices (VADs) Based on End-User Hospitals and clinic Specialized Cardiovascular Disease Treatment Centers Ambulatory surgery centers Regional Coverage Analysis Based on Region North America Europe Asia-Pacific Middle-East and Africa Latin America Segments Analysis & Insights By Product Type, Implantable Cardioverter Defibrillators (ICDs) are the largest in congestive heart failure treatment devices due to technological innovations. As a result, the ventricular assist devices (VADs) market is predicted to develop significantly throughout the forecast period. By End-users, the Hospitals segment is expected to grab the congestive heart failure devices market share. The rise of government funds for the development of hospitals across the globe is expected to drive the market growth of this segment. According to a study published in NCBI, Total medical costs in the US are projected to increase from $31.1 billion (in 2020) to $53.1 billion (by 2030). Most (80%) of the costs attributed to HF are related to hospitalization, assuming the continuation of current hospitalization practices. By Region, North America is predicted to be the largest market for congestive heart failure devices, followed by Europe due to the high frequency of cardiovascular disorders. According to AHA's Heart Disease and Stroke Statistics 2017, the number of people diagnosed with heart failure in the US is increasing and projected to rise by 46 percent by 2030, resulting in more than 8 Mn people with heart failure. The region has witnessed more stress due to financial issues, workplace atmosphere, and other family problems. According to World Economic Forum Report, workers in the US and Canada recorded the highest daily stress levels globally at 57%. The percolating effects of the ongoing stress and trauma are precarious for the country's youth, Generation Z (Gen Z). According to the APA's 2020 Stress in America study, Gen Z is more stressed than Millenials, Gen X, Baby Boomers, or older adults. Because of the growing geriatric population in India and China, the Asia-Pacific region is expected to be the fastest Growing Market in congestive heart failure treatment devices. Congestive Heart Failure Treatment Devices Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 17.53 billion The revenue forecast in 2030 USD 35.96 billion Growth rate CAGR of 8.31% The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Product, By End User, By Region By Product Cardiac Pacemaker, Cardiac Resynchronization Therapy (CRT), Implantable Cardioverter Defibrillators (ICDs), Counter Pulsation Devices, Ventricular Assist Devices (VADs) By End-User Hospitals and clinics, Specialized Cardiovascular Disease Treatment Centers, Ambulatory surgery centres By Region Asia Pacific, North America, Europe, and LAMEA Country Scope US, Mexico, Canada, Germany, UK, France, China, Japan, India etc. Company Usability Profiles Berlin Heart GmbH, Abiomed, Inc., Biotronik SE & Co. KG, Boston Scientific Corporation, HeartWare International, Inc., Jarvik Heart, Inc., LivaNova PLC, Medtronic plc, ReliantHeart Inc., and St. Jude Medical, Inc. Pricing and purchase options Customized buying options are available to meet your exact research needs. Global Congestive Heart Failure Treatment Devices Market Competitive Landscape Analysis This global CHF treatment devices industry report has the competitive landscape analysis, which details the most significant competitors operating in a global market. The comparison is based on overall revenue generation, market initiatives, company overview, R&D investment, production analysis, value chain optimization, market share financials, company strengths and weaknesses, global presence, heart failure device companies, production capacity, production sites and facilities, market potential, and other variables. • Medtronic • Abiomed • Berlin Heart GmbH • Biotronik SE & Co. KG • Boston Scientific Corporation • Jarvik Heart • LivaNova PLC • HeartWare International • ReliantHeart • CVRx • St. Jude Medical Recent Developments In March 2022, FineHeart's ICOMS FLOWMAKER Algorithms were granted a patent in the United States. The ICOMS FLOWMAKER, the world's first and only fully implantable electrophysiological cardiac support device for treating severe heart failure, is covered by the patent "Method for managing a heart pump." The business expects to treat 200,000 patients with severe heart failure every year. In February 2022, US FDA approved Jardiance (empagliflozin) to treat adults with heart failure. Jardiance became the first and only heart failure medication to show a statistically significant reduction in heart failure-related deaths and hospitalizations, independent of ejection fraction. Also, it reduces the risk of cardiovascular death in adults with type 2 diabetes having cardiovascular disease and lower blood sugar. In March 2021, BERLIN HEALS received Breakthrough Device Designation (BDD) from FDA for its Device for Cardiac Microcurrent Therapy ("C-MIC"). The C-MIC is an implanted device that uses two electrodes to supply a steady, low-current electrical DC to the heart. The FDA's Breakthrough Devices program helps companies create medical devices that have the potential to treat or diagnose life-threatening or profoundly debilitating diseases. In January 2020, FAST BioMedical Announced the Successful Completion of the Multi-center Acute Congestive Heart Failure Trial in Germany. The measures developed by FAST BioMedical has the potential to be a game-changer in managing volume and volume-related kidney damage in patients with acute congestive heart failure. Various Devices that Key Market Leaders Develop Product Function Key players PLATINIUM ICDs and CRT-Ds Liva Nova Freezor For treatment of a common heart rhythm condition Medtronic BAROSTIM NEO Neuromodulation Device (regulate heart, kidney and vascular function) CVRx Rivacor Heart monitoring at home Biotronic Frequently Asked Question About This Report What is the latest treatment for heart failure? Recently the FDA approved Entresto, a combination of sacubitril and valsartan, for the treatment of heart failure patients with preserved ejection fraction (HFpEF) What is the first-line treatment for congestive heart failure? Loop diuretics should be used first, with thiazides added if the fluid overload is refractory. After that, patients should take diuretic treatment with a ß-blocker, a low-salt diet, and an ACE inhibitor. How to manage congestive heart failure at home? Modify daily activities, avoid stress, take enough rest, take a heart-healthy diet, and maintain low sodium and fat intake. However, special care has to be taken for patients with low haemoglobin, thyroid disease, diabetes and kidney disease. What treatment is used for congestive heart failure? Modern treatment for heart disease includes Cardiac catheterization, Cardiac resynchronization therapy, and Coronary artery bypass surgery. Some congestive heart failure devices used are Echocardiogram, Electrocardiogram (EKG or ECG), Implantable cardioverter-defibrillator and others. Also, NCBI has recommended some mobile apps for heart failure patients. How treatable is CHF? CHF is not curable, but early detection and treatment are possible. Following a proper treatment plan that includes lifestyle changes may help improve their quality of life. What are the four pillars of heart failure treatment? The four pillars are diuretics, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and Lanoxin. How big is the congestive heart failure treatment devices market? The global congestive heart failure treatment devices market size was $17.53 Bn in 2021 and is predicted to reach $35.96 Bn by 2030, with a CAGR of 8.31%. What is the congestive heart failure treatment devices market growth? The global congestive heart failure treatment devices market is expected to grow at a compound annual growth rate (CAGR) of 8.31% from 2021 to 2030 to reach USD35.96 billion by 2030. Sources https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationAgeing2019-Report.pdf https://www.gallup.com/analytics/349280/gallup-global-emotions-report.aspx https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930493/ https://www.cdc.gov/heartdisease/heart_failure.htm 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at Market size By bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size By Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global Market 4.2.1 Global Congestive Heart Failure (CHF) Treatment Devices Market, 2020 – 2028 (USD Million) 4.3 Regional Analysis 4.3.1 Global Market, By Region, 2021-2030 (USD Million) 4.4 Product Type Analysis 4.4.1 Global Market, By Product Type, 2021-2030 (USD Million) 4.5 End-User Analysis 4.5.1 Global Market, By End-User, 2021-2030 (USD Million) 4.6 Value Chain Analysis 4.7 Market Variable Analysis 4.7.1 Market Drivers Analysis 4.7.2 Market Restraints Analysis 4.8 Business Environment Analysis Tool 4.8.1 Market PEST analysis 4.8.2 Market Porter’s analysis 4.9 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Technology Analysis 5.11.1. Trends in Technology (2014-2020) 5.11.2. Trends in Technology (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By region, By Countries) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Product Type 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global Market: By Product Type Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Cardiac Pacemaker 7.3.1. Cardiac Pacemaker Market, 2021-2030 (USD Million) 7.4. Implantable Cardioverter Defibrillators 7.4.1. Implantable Cardioverter Defibrillators Market, 2021-2030 (USD Million) 7.5. Cardiac Resynchronization therapy devices 7.5.1. Cardiac Resynchronization therapy devices Market, 2021-2030 (USD Million) 7.6. Counter Pulsation Devices 7.6.1. Counter Pulsation Devices Market, 2021-2030 (USD Million) 7.6. Ventricular Assist Devices (VADs) 7.6.1. Ventricular Assist Devices (VADs) Market, 2021-2030 (USD Million) 8. Global Market: By End-User Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Hospitals and clinic 8.3.1. Hospitals and clinic Market, 2021-2030 (USD Million) 8.4.Specialized Cardiovascular Disease Treatment Centres 8.4.1. Specialized Cardiovascular Disease Treatment Centres Market, 2021-2030 (USD Million) 8.5 Ambulatory surgery centres 8.5.1 Ambulatory surgery centres Market, 2021-2030 (USD Million) 9. Global Market: Regional Outlook 9.1 North America 9.1.1. North America Market, By Product Type, 2021-2030 (USD Million) 9.1.4. North America Market, By End-User, 2021-2030 (USD Million) 9.1.5. North America Market, By Country, 2021-2030 (USD Million) 9.1.4.1. U.S. 9.1.4.1.1. U.S. Market, By Product Type, 2021-2030 (USD Million) 9.1.4.2. Canada 9.1.4.2.1. Canada Market, By Product Type, 2021-2030 (USD Million) 9.1.4.2.2. Canada Market, By Region, 2021-2030 (USD Million) 9.1.4.2.3. Canada Market, By End-Users, 2021-2030 (USD Million) 9.2. Europe 9.2.1. Europe Market, By Product Type, 2021-2030 (USD Million) 9.2.2. Europe Market, By End-User, 2021-2030 (USD Million) 9.2.5. Europe Market, By country, 2021-2030 (USD Million) 9.2.4.1 U.K. 9.2.4.1.1. U.K. Market, By Product Type, 2021-2030 (USD Million) 9.2.4.1.2. U.K. Market, By End-Users, 2021-2030 (USD Million) 9.2.4.1.3. U.K. Market, By Region, 2021-2030 (USD Million) 9.2.4.2. Germany 9.2.4.2.1. Germany Market, By Product Type, 2021-2030 (USD Million) 9.2.4.2.2. Germany Market, By End-User, 2021-2030 (USD Million) 9.2.4.2.3. Germany Market, By Region, 2021-2030 (USD Million) 9.2.4.3. France 9.2.4.3.1. France Market, By Product Type, 2021-2030 (USD Million) 9.2.4.3.2. France Market, By Region, 2021-2030 (USD Million) 9.2.4.3.3. France Market, By End-User, 2021-2030 (USD Million) 9.2.4.4. Rest of Europe 9.2.4.4.1. Rest of Europe Market, By Product Type, 2021-2030 (USD Million) 9.2.4.4.2. Rest of Europe Market, By Region, 2021-2030 (USD Million) 9.2.4.4.3. Rest of Europe Market, By End-User, 2021-2030 (USD Million) 9.3. Asia Pacific 9.3.1. Asia Pacific Market, By Product Type, 2021-2030 (USD Million) 9.3.2. Asia Pacific Market, By End-User, 2021-2030 (USD Million) 9.3.5. Asia Pacific Market, By country, 2021-2030 (USD Million) 9.3.4.1. China 9.3.4.1.1. China Market, By Product Type, 2021-2030 (USD Million) 9.3.4.1.2. China Market, By Region, 2021-2030 (USD Million) 9.3.4.1.3. China Market, By End-User, 2021-2030 (USD Million) 9.3.4.2. India 9.3.4.2.1. India Market, By Product Type, 2021-2030 (USD Million) 9.3.4.2.2. India Market, By Region, 2021-2030 (USD Million) 9.3.4.2.3. India Market, By End-User, 2021-2030 (USD Million) 9.3.4.3. Japan 9.3.4.3.1. Japan Market, By Product Type, 2021-2030 (USD Million) 9.3.4.3.3. Japan Market, By End-User, 2021-2030 (USD Million) 9.3.4.4. South Korea 9.3.4.4.1. South Korea Market, By Product Type, 2021-2030 (USD Million) 9.3.4.4.3. South Korea Market, By End-User, 2021-2030 (USD Million) 9.3.4.5. Rest of ASIA PACIFIC 9.3.4.5.1. Rest of ASIA PACIFIC Market, By Product Type, 2021-2030 (USD Million) 9.3.4.5.3. Rest of ASIA PACIFIC Market, By End-User, 2021-2030 (USD Million) 9.4. Latin America 9.4.1. Latin America Market, By Product Type, 2021-2030 (USD Million) 9.4.3. Latin America Market, By End-User, 2021-2030 (USD Million) 9.4.4. Latin America Market, By country, 2021-2030 (USD Million) 9.4.4.1. Brazil 9.4.4.1.1. Brazil Market, By Product Type, 2021-2030 (USD Million) 9.4.4.1.3. Brazil Market, By End-User, 2021-2030 (USD Million) 9.4.4.2. Mexico 9.4.4.2.1. Mexico Market, By Product Type, 2021-2030 (USD Million) 9.4.4.2.3. Mexico Market, By End-User, 2021-2030 (USD Million) 9.4.4.3. Rest of the Latin America 9.4.4.3.1. Rest of the Latin America Market, By Product Type, 2021-2030 (USD Million) 9.4.4.3.3. Rest of the Latin America Market, By End-User, 2021-2030 (USD Million) 9.5. MEA 9.5.1. MEA Market, By Product Type, 2021-2030 (USD Million) 9.5.3. MEA Market, By End-User, 2021-2030 (USD Million) 10. Competitive Landscape 10.1 Medtronic. 10.1.1. Company overview 10.1.2. Financial performance 10.1.3. ProductPortfolio Analysis 10.1.4. Business Strategy & Recent Development 10.2. Abiomed. 10.2.1. Company overview 10.2.2. Financial performance 10.2.3. Product Portfolio Analysis 10.2.4. Business Strategy & Recent Development 10.3. Berlin Heart GmbH. 10.3.1. Company overview 10.3.2. Financial performance 10.3.3. Product Portfolio Analysis 10.3.4. Business Strategy & Recent Development 10.4. Biotronik SE & Co. KG. 10.4.1. Company overview 10.4.2. Financial performance 10.4.3. Product Portfolio Analysis 10.4.4. Business Strategy & Recent Development 10.5. Boston Scientific Corporation 10.5.1. Company overview 10.5.2. Financial performance 10.5.3. Product Portfolio Analysis 10.5.4. Business Strategy & Recent Development 10.6. Jarvik Heart. 10.6.1. Company overview 10.6.2. Financial performance 10.6.3. Product Portfolio Analysis 10.6.4. Business Strategy & Recent Development 10.7. LivaNova PLC. 10.7.1. Company overview 10.7.2. Financial performance 10.7.3. Product Portfolio Analysis 10.7.4. Business Strategy & Recent Development 10.8. HeartWare International. 10.8.1. Company overview 10.8.2. Financial performance 10.8.3. Product Portfolio Analysis 10.8.4. Business Strategy & Recent Development 10.9. ReliantHeart. 10.9.1. Company overview 10.9.2. Financial performance 10.9.3. Product Portfolio Analysis 10.9.4. Business Strategy & Recent Development 10.10. CVRx. 10.10.1. Company overview 10.10.2. Financial performance 10.10.3. Product Portfolio Analysis 10.10.4. Business Strategy & Recent Development 10.11. St. Jude Medical. 10.11.1. Company overview 10.11.2. Financial performance 10.11.3. Product Portfolio Analysis 10.11.4. Business Strategy & Recent Development List of Tables (45 Tables) TABLE 1. MARKET, By Product Type, 2021-2030 (USD Million) TABLE 2. MARKET FOR Cardiac Pacemaker, BY REGION, 2021-2030 (USD Million) TABLE 3. MARKET FOR Implantable Cardioverter Defibrillators, BY REGION, 2021-2030 (USD Million) TABLE 4. MARKET FOR Cardiac Resynchronization therapy devices, BY REGION, 2021-2030 (USD Million) TABLE 5. MARKET FOR Counter Pulsation Devices, BY REGION, 2021-2030 (USD Million) TABLE 5. MARKET FOR Ventricular Assist Devices (VADs), BY REGION, 2021-2030 (USD Million) TABLE 6. MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 7. MARKET FOR Hospitals and clinic, BY REGION, 2021-2030 (USD Million) TABLE 8. MARKET FOR Specialized Cardiovascular Disease Treatment Centres, BY REGION, 2021-2030 (USD Million) TABLE 9. MARKET FOR Ambulatory surgery centres, BY REGION, 2021-2030 (USD Million) TABLE 10. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 11. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 12. NORTH AMERICA MARKET, BY End-Users, 2021-2030 (USD Million) TABLE 13. NORTH AMERICA MARKET, By Product Type, 2021-2030 (USD Million) TABLE 14. NORTH AMERICA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 15. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 16. EUROPE MARKET, By Product Type, 2021-2030 (USD Million) TABLE 17. EUROPE MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 18. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 19. ASIA-PACIFIC MARKET, By Product Type, 2021-2030 (USD Million) TABLE 20. ASIA-PACIFIC MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 21. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 22. LAMEA MARKET, By Product Type, 2021-2030 (USD Million) TABLE 23. LAMEA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 24. Medtronic: COMPANY SNAPSHOT TABLE 25. Medtronic: OPERATING SEGMENTS TABLE 26. Abiomed: COMPANY SNAPSHOT TABLE 27. Abiomed: OPERATING SEGMENTS TABLE 28. Berlin Heart GmbH: COMPANY SNAPSHOT TABLE 29. Berlin Heart GmbH: OPERATING SEGMENTS TABLE 30. Biotronik SE & Co. KG: COMPANY SNAPSHOT TABLE 31. Biotronik SE & Co. KG: OPERATING SEGMENTS TABLE 32. Boston Scientific Corporation: COMPANY SNAPSHOT TABLE 33. Boston Scientific Corporation: OPERATING SEGMENTS TABLE 34. Jarvik Heart: COMPANY SNAPSHOT TABLE 35. Jarvik Heart: OPERATING SEGMENTS TABLE 36. LivaNova PLC: COMPANY SNAPSHOT TABLE 37. LivaNova PLC: OPERATING SEGMENTS TABLE 38. HeartWare International: COMPANY SNAPSHOT TABLE 39. HeartWare International: OPERATING SEGMENTS TABLE 40. ReliantHeart: COMPANY SNAPSHOT TABLE 41. ReliantHeart: OPERATING SEGMENTS TABLE 42. CVRx: COMPANY SNAPSHOT TABLE 43. CVRx: OPERATING SEGMENTS TABLE 44. St. Jude Medical: COMPANY SNAPSHOT TABLE 45. St. Jude Medical: OPERATING SEGMENTS List of Figures (20 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Product-Based Estimation Figure 6 Top 11 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Import Data for , By Country, 2016–2020 (USD Thousand) Figure 9 Export Data for , By Country, 2016–2020 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By End-Users, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By Product Type, 2019 vs. 2025 Figure 13 Geographical Snapshot of the Market Figure 14 Implantable Cardioverter Defibrillators Higher CAGR in the Market for Product Type Segment during Forecast Period. Figure 15 Hospitals and clinic to Witness Higher CAGR in the Market for End-User Segment during Forecast Period. Figure 16 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 17 Market: Drivers, Restraints, Opportunities, and Challenges Figure 18 North America: Market Snapshot Figure 19 Asia Pacific: Market Snapshot Figure 20 Vendor Dive: Evaluation Overview